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Abstract: Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic 
receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption 
and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes 
such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality 
have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality 
due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some sub-
groups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the 
2-adrenergic receptor and those with a high percentage of neutrophils in sputum. 
Keywords: Tiotropium bromide, COPD, lung function, COPD mortality, COPD exacerbations, quality of life. 
INTRODUCTION 
  Chronic obstructive lung disease (COPD) is a widespread 
chronic disease that mainly affects long-term smokers. As its 
name indicates, it is characterized by airway irreversibility. 
To date, the results of treatment for this disease have been 
relatively disappointing and no drug has proved able to re-
verse, or even to check, its development. In this paper we 
review the properties, pharmacological and clinical effects of 
tiotropium bromide, the latest drug to come on the market 
for treatment of chronic lung obstruction. 
DRUG CHARACTERISTICS 
  Tiotropium bromide is a synthetic quaternary anticho-
linergic agent approved for maintenance therapy in stable 
COPD. It has two important properties: it is functionally 
selective for specific muscarinic receptors that mediate air-
way smooth-muscle contraction, and it has a long duration of 
action, making it well suited for once-daily dosing. Tiotro-
pium works by blocking the muscarinic receptors for the 
neurotransmitter acetylcholine (Ach), which is released from 
cholinergic nerve endings in the airways. As tiotropium 
bromide is electrically charged, it is not absorbed by the 
gastrointestinal tract and does not pass the blood-brain bar-
rier. This means that it does not have  characteristic side 
effects of anticholinergic agents, particularly those affecting 
the central nervous system. 
MUSCARINIC RECEPTORS IN THE AIRWAYS AND 
TIOTROPIUM BROMIDE 
  Three muscarinic receptor subtypes have been found in 
human airways, with different functions: M1, M2 and M3 [1]. 
Autoradiographic mapping has shown that these receptors 
are mainly localized in the smooth muscle of all airways, 
although they reach their highest density in the proximal 
airways and in submucosal glands [2]. 
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 M 1 receptors are localized in parasympathetic ganglia in 
the airway, where they function as regulators of ganglionic 
transmission (Fig. 1). Preganglionic nerves release Ach, 
which acts on th nicotinic receptors of the ganglionic cells to 
activate postganglionic nerves. M1 receptors facilitate neuro-
transmission through these ganglia, thereby enhancing the 
cholinergic bronchoconstrictor reflex [3]. Therefore, block-
ing M1 receptors will be beneficial in COPD patients. 
 M 2 receptors are located on cholinergic nerve endings 
and act as autoreceptors which inhibit acetylcholine release 
from those nerve terminals [4], thereby providing feedback 
inhibition (Fig. 1). Drugs block M2, increasing Ach release, 
and thus increasing bronchoconstrictor responses. 
 M 3 receptors are expressed in the smooth muscle of all 
airways (Fig. 1). The bronchoconstrictor response to choliner-
gic nerve stimulation and cholinergic agonists is mediated by 
M3 [5]. These receptors also mediate mucus secretion in re-
sponse to cholinergic agonists [6]. For this reason, blockade of 
M3 receptors is the main objective of anticholinergic therapy 
in COPD. The major side effects of anticholinergic drugs – 
dry mouth, glaucoma, and urinary retention – are all mediated 
by M3 receptors, so their frequency cannot be reduced. 
  Therefore, optimal inhibition of parasympathetic activity 
may be achieved by selective antagonism of the M3 and M3 
receptors, sparing the M3 receptors. Tiotropium bromide 
dissociates more slowly from M1 and M3 receptors than M2 
receptors and for this reason has kinetic selectivity [7]; be-
cause of its sustained activity, once-daily administration is 
possible. Tiotropium bromide binds to muscarinic receptors 
with high affinity and is approximately 10 times more potent 
than ipratropium bromide in binding to human lung mus-
carinic receptors [8]. Ipratropium bromide and oxitropium 
bromide are nonselective blockers; consequently, they block 
M2 receptors, thereby increasing Ach release at nerve end-
ings, which may reduce the degree of blockade or the dura-
tion of action [4]. 
  It has been demonstrated that the slow dissociation of 
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long duration effect [7]. Though the two compounds have 
similar pharmacokinetic profiles, tiotropium’s duration of 
action is more than 24-h, while ipratropium action lasts only 
six hours [9]. Studies using recombinant receptors have 
shown that tiotropium has a much slower rate of dissociation 
from M3 muscarinic receptors than ipratropium [10], and 
conclude that this feature determines the difference in dura-
tion of action between the drugs [7]. 
  The approved dose of tiotropium is 18μg qd, preferably 
administered in the morning [11]. As bronchodilation tends 
to increase over the first week of daily administration, this 
dose is best used on a regular daily basis. Since tiotropium 
may take several hours to reach its peak effect, it is not rec-
ommended for rapid relief of dyspnea. A bronchodilator 
reversibility test prior to prescription does not predict its 
long-term benefits [12]. 
  Tiotropium has been shown to reduce the frequency of 
exacerbations, but its effect on airway inflammation is un-
clear. A placebo-control trial investigating its effect on in-
flammation parameters such as sputum and serum cytokines 
found an association with a reduced frequency of exacerba-
tion, but there was no difference in airway or systemic in-
flammation [13]. A recent study [14] proposes that tiotro-
pium may have a beneficial influence on airway remodeling 
in chronic airway diseases through its antiproliferative ef-
fects on fibroblasts and myofibroblasts. 
THE ROLE OF TIOTROPIUM IN THE MANAGE-
MENT OF COPD 
  There is some evidence that the cholinergic tone of the 
airways is increased in patients with COPD [16]. In fact 
vagal cholinergic tone is the main reversible element of 
airway obstruction in COPD, and its effects are exaggerated 
by geometric factors due to narrowed airways, because air-
way resistance is inversely proportional to the fourth power 
of the airway radius [17]. 
  Tiotropium significantly improves bronchodilation, 
hyperinflation, dyspnea, health status, exacerbations and 
mortality in COPD patients, but it does not decrease the rate 
of FEV1 decline in COPD. 
BRONCHODILATION 
  The degree of acute improvement in spirometry indices 
after bronchodilator inhalation varies among COPD patients, 
and depends on the type and dose of bronchodilator as well 
as the timing of administration. The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) defines COPD 
as a disease characterized by a partially reversible airflow 
limitation [18]. Patients with COPD are commonly thought 
to present a lower acute bronchodilator response than asth-
matics, although a high percentage of patients with COPD 
respond to high doses of 2 adrenergic receptors [19]. 
Moreover, more than half of COPD patients who do not 
significantly respond to 2 adrenergic receptors have posi-
tive bronchodilator tests when high doses of inhaled anticho-
linergics are administered [20]. A recent trial in a large co-
hort of patients with moderate-to-very-severe COPD found 
significant increases in lung function in most patients who 
received 80 g ipratropium followed by 400 g salbutamol. 
The percentage of patients considered as responders differed 
depending upon the criterion applied [21]. Almost two-thirds 
(65.6%) of patients met at least one common criterion for 
FEV1 responsiveness following acute administration of 
bronchodilators [22]. 
  FEV1 has been shown to rise slowly after tiotropium 
administration, reaching a peak between 1 to 3 h after the 
 
Fig. (1). Muscarinic receptor subtypes in airways. M1 are localized to parasympathetic ganglia. M2 on postganglionic cholinergic nerve 
terminals inhibit the release of Ach. M3 that constrict airway smooth muscle. Adapted from Barnes PJ [15]. 
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inhalation. The peak response is followed by a plateau sig-
nificantly higher than placebo, lasting up to 32 h [9]. 
  Tiotropium has shown an effective bronchodilation effect 
following single administrations of doses of between 10 and 
80 mg [9]. All subsequent studies have used a daily dose of 
18 mg. After drug withdrawal, patients’ FEV1 gradually 
returned to baseline levels over a period of approximately 3 
weeks, indicating that the drug exerted a prolonged effect 
[23]. 
  Repeated daily use of tiotropium offers persistent bron-
chodilation. The FEV1 24 hours post-dose (and before the 
next dose), its “trough” value, progressively increases over 
the first few days of regular administration. Van Noord et al. 
[24] found that the trough FEV1 increased by 0.19 L (18% 
above the initial baseline) after 8 days of daily administra-
tion, most of this increase having occurred by the second 
day. Trough FVC continued to rise daily during the first 
week and had increased by 0.67 L (27% above its initial 
baseline) by day 8. 
  The results of large long-term trials indicate that tiotro-
pium administered once daily raises the trough FEV1 by 0.1 
to 0.15 L, and raises the peak FEV1 by a further 0.15 to 0.20 
L. In both cases, its effect is significantly higher than that of 
either ipratropium administered four times daily or sal-
meterol administered twice daily. No loss of efficacy was 
seen over the course of one year of regular treatment with 
tiotropium. Therefore, it appears that the difference at the 
end of the trial may be due, at least to some extent, to the 
fact that the response to tiotropium was maintained, whereas 
the response to salmeterol decreased over the course of the 
study, suggesting the development of tachyphylaxis [25-28] 
  In the UPLIFT study [29], the mean FEV1 value in the 
tiotropium group after the bronchodilation test showed a 
significant improvement compared with the placebo group, 
which was maintained throughout the study. This improve-
ment ranged from 47 to 65 ml after bronchodilation 
(p<0.001) (Fig. 2). The tiotropium group also showed a sig-
nificant improvement in the FEV1 before bronchodilation, 
ranging from 87 to 103 ml (p< 0.001) (Fig. 2). But in pa-
tients with stable COPD there was little difference in bron-
chodilation when adding higher than conventional doses of 
salbutamol or ipratropium bromide to tiotropium. This is an 
interesting finding, especially for COPD patients suffering 
from cardiovascular co-morbidities [30]. On the other hand, 
in patients with COPD the addition of formoterol once or 
twice daily to tiotropium once daily improves airflow ob-
struction, resting hyperinflation, and the use of rescue salbu-
tamol [31]. No such improvement was found when we added 
salmeterol to tiotropium [32]. 
HYPERINFLATION 
  In COPD patients, hyperinflation is reflected by a signifi-
cant increase in static lung volumes. Lung volume changes 
correlate better with impairment of patient functional capa-
bilities than airflow limitations [33]. The systematic use of 
tiotropium may produce a significant reduction in lung infla-
tion. 
  The inspiratory capacity (IC) is a parameter that can be 
measured by spirometry and its increase indirectly reflects a 
decrease in hyperinflation [34, 35]. In patients with COPD 
receiving 4-week treatment with tiotropium versus placebo 
the functional residual capacity was substantially reduced 
and IC was increased in the treated group, indicating a reduc-
tion in hyperinflation that did not occur in the placebo group 
[36] (Fig. 3). Another clinical trial found that the reduction 
in hyperinflation led to an increase in the tidal volume during 
constant work-rate cycle ergometry, with an improvement in 
endurance time of approximately 21%. The dyspnea index 
also improved after six weeks of treatment [37]. 
 Recently,  Gelb  et al. studied the protection of tiotropium 
against dynamic hyperinflation in COPD phenotypes. Em-
physema was evaluated by high-resolution thin-section lung 
scan. Spirometry (including inspiratory capacity) was meas-
 
Fig. (2). Mean forced expiratory volume in 1 second before and after bronchodilation from day 30 to the end of the study. From Tashkin et 
al. [29]. 
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ured before and immediately after metronome-paced hyper-
ventilation to induce dynamic hyperinflation. Tiotropium 
increased IC in moderate-severe COPD, independently of the 
severity of lung emphysema. Despite bronchodilation and 
lower resting lung volume, tiotropium did not decrease the 
induced dynamic hyperinflation, which was also independent 
of underlying emphysema [38]. 
 
Fig. (3). Changes in lung volumes and spirometry following treat-
ment with tiotropium or placebo after 4 weeks. All differences 
between treatments were significant (p<0.01). From Celli et al. 
[36]. 
DYSPNEA 
  In COPD patients, dyspnea correlates more closely with 
hyperinflation than FEV1 [33, 34]. The effect of tiotropium 
on this symptom has been measured by Mahler’s transition 
dyspnea index (TDI) [39] for the dyspnea incurred by activi-
ties of daily living in COPD. The improvement in TDI in 
patients receiving tiotropium has been shown to be statisti-
cally higher than placebo and ipratropium at all time points 
over a 12-month period and tends to increase as treatment 
progresses [25, 26]. In the studies comparing salmeterol 
versus tiotropium, the improvement in TDI with tiotropium 
was greater than with salmeterol [27-28] although this dif-
ference only reached statistical significance in one study 
[27]. COPD symptoms can be measured indirectly with the 
use of a rescue short-acting 2-agonist. A treatment that 
effectively reduces symptoms should also reduce the need 
for rescue medication; studies have shown that tiotropium 
performs better than both placebo and ipratropium [25, 26]. 
  Pulmonary rehabilitation has been shown to improve 
exercise tolerance as well as dyspnea [40, 41]. In a placebo-
controlled trial, Casaburi et al. [42] tested the hypothesis that 
improvement in ventilatory mechanics resulting from tiotro-
pium treatment may enhance patients’ training of muscles 
involved in deambulation and therefore increase exercise 
tolerance and the benefits of pulmonary rehabilitation. In 
that study, tiotropium in combination with pulmonary reha-
bilitation improved endurance of a constant work-rate tread-
mill task and produced clinically significant improvements 
in dyspnea and health status compared with pulmonary reha-
bilitation alone. In addition, improvements with tiotropium 
were sustained for three months after completion of pulmo-
nary rehabilitation [42]. 
HEALTH STATUS 
  The effects of tiotropium on health status have been 
measured in several studies. The St. George’s Respiratory 
Questionnaire score, measured in long-term studies, im-
proved significantly with tiotropium treatment compared to 
baseline, placebo [25, 27, 28] or ipratropium [26], but not 
compared to sameterol [27, 28]. 
  In the one-year tiotropium trials using The Medical Out-
comes Study Short Form-36, a generic health status instru-
ment, the domains of role-physical and physical health 
summary scores significantly improved in the tiotropium 
group compared to the control groups [25-28]. 
  In the UPLIFT study [29], 2478 patients treated with 
tiotropium and 2337 patients receiving placebo were in-
cluded. 
  The treated group showed significant differences at all 
time points for the mean absolute change in the SGRQ total 
score, although the differences were not considered to be 
clinically significant. However, a higher proportion of pa-
tients in the tiotropium group compared to the placebo group 
had an improvement of four points or more in the SGRQ 
total scores from baseline at the end of the fourth year of 
treatment (Fig. 4). 
ACUTE EXACERBATIONS 
  Late stage COPD is characterized by increased frequency 
and severity of exacerbations, which account for most of the 
condition’s economic burden. Exacerbations are associated 
with worse prognosis and increased mortality, especially 
those that require hospital admission [43]. 
  The effect of tiotropium treatment on the incidence of 
acute exacerbations has been considered as a secondary 
outcome in several studies.  Modifying the criteria of An-
thonisen et al. [44], exacerbations in the tiotropium studies 
were defined as an increase in two or more respiratory symp-
toms for at least three days. Casaburi et al. [25] enrolled 921 
patients with stable COPD in two identical randomized one-
year double-blind placebo-control studies, and found signifi-
cantly fewer exacerbations in the tiotropium group than in 
the placebo group (20% reduction). There was a significant 
increase in the time to first exacerbations in the tiotropium 
group compared to placebo. The proportion of patients expe-
riencing at least one COPD exacerbation was lower in the 
tiotropium group (36%) than in the placebo group (42%) 
(14% reduction, p< 0.05). In addition, significantly fewer 
hospitalizations were associated with exacerbations in the 
tiotropium cohort compared to the placebo group (47% re-
duction). The proportion of patients hospitalized for exacer-
bations was lower in the tiotropium group than in the pla-
cebo group (41% reduction, p > 0.05). 
  Another trial [28] recorded exacerbations in 1207 pa-
tients with COPD during six months’ treatment with tiotro-
pium, salmeterol, or matching placebos. Compared with 
placebo, tiotropium, but not salmeterol, was associated with 
a delay in the onset of the first exacerbation. Fewer COPD 
exacerbations/patient-year occurred in the tiotropium group 
than in the placebo group (p<0.05); there were no differences 
between the salmeterol and the placebo groups. The tiotro-
pium group showed 0.10 hospital admissions per patient-
year per COPD exacerbation, compared with rates of 0.17 
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for salmeterol and 0.15 for placebo (non-significant differ-
ences). 
  The INSPIRE study [45] was the first large-scale trial to 
evaluate the impact of two different treatment approaches – 
tiotropium or the combination using salmeterol and flutica-
sone propionate – on COPD exacerbations over a 2-year 
period. Methodological issues need to be considered when 
interpreting these results (see the mortality section). The 
estimated overall rates of exacerbations were 1.28 per year 
with the combination and 1.32 per year for tiotropium; the 
ratio (0.967) indicated that there was no difference between 
the rates. The incidence of exacerbations requiring hospitali-
zations was 16% for salmeterol and fluticasone propionate, 
and 13% for tiotropium. 
  Two meta-analyses evaluating the effectiveness of tiotro-
pium bromide compared to placebo, ipratropium bromide or 
a long-acting beta-agonist for the treatment of stable COPD 
patients showed that tiotropium notably reduced the exacer-
bations and related hospitalizations compared with placebo, 
 
Fig. (4). Tiotropium significantly increases the percentage of patients with an improvement 4 units in the total score of the SRGQ*. File 
data, Boehringer Ingelheim/Pfizer. 
 
Fig. (5). Kaplan- Meier curves show the cumulative incidence estimate of the probability of COPD exacerbation at day 1470. All patients 
who received at least one dose of a study drug were included in the analysis. From Tashkin et al. [29]. 
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but no statistical differences were found with respect to the 
long-acting beta2-agonist (LABA) [46, 47]. 
  Two recent trials have evaluated the potential benefits of 
associating tiotropium with LABA and inhaled corticoster-
oids. Aaron et al. [32] report the results of the first clinical 
study in moderate to severe COPD after one year of follow-
up in three groups of patients receiving tiotropium plus pla-
cebo, tiotropium plus salmeterol and tiotropium plus flutica-
sone-salmeterol. Similar proportions of patients experienced 
an exacerbation across all three groups, but those who re-
ceived tiotropium plus fluticasone-salmeterol presented 
lower levels of COPD and all-cause hospitalizations com-
pared with those who received tiotropium plus placebo. The 
addition of salmeterol to tiotropium had no effect on hospi-
talization rates compared to tiotropium alone. A limitation of 
the study is the sizable proportion of patients (approximately 
40%) who did not receive the assigned treatment throughout 
the study. 
  In the UPLIFT study, exacerbations were considered a 
secondary outcome [29]. The trial compared four years of 
therapy with either tiotropium or placebo in patients with 
COPD who were permitted to use all respiratory medications 
except inhaled anticholinergic drugs. Tiotropium was associ-
ated with a 14% reduction in the mean number of exacerba-
tion (p>0.001). The drug was associated with a significant 
delay in the time to the first hospitalization for an exacerba-
tion (Fig. 5). Tiotropium was also associated with a signifi-
cant delay in the time to the first exacerbation: a median of 
16.7 months (95% CI: 14.9 to 17.9) compared with one of 
12.5 months (95% CI: 11.5 to 13.8) in the placebo group. 
MORTALITY 
  In patients with COPD, all-cause mortality significantly 
decreases after smoking cessation. Mortality did not signifi-
cantly differ in patients receiving ipratropium bromide or 
placebo [48]. Comparing four groups of patients receiving 
almeterol, fluticasone propionate, both drugs or placebo with 
death from any cause as the primary outcome, the TORCH  
 
study [49] found all-cause mortality rates to be similar in the 
four arms. 
  Mortality was a secondary outcome in a 104-week long 
trial [45] comparing the clinical efficacy of treatment with a 
fixed combination of salmeterol/fluticasone propionate and 
tiotropium bromide. Mortality was significantly lower in the 
salmeterol/fluticasone propionate group: 3% of patients in 
this group died, compared with 6% in the tiotropium group 
(p=0.032). However, methodological issues need to be con-
sidered when interpreting these results [50]. In this study 
[45] the design imposed discontinuation of inhaled corticos-
teroids followed by a 2-week run-in of oral prednisolone and 
salmeterol prior to randomization, which may have affected 
outcomes [51]. Other effects were likely due to the abrupt 
interruption of the run-in regimen. Another methodological 
problem that hampers the interpretation of the results is the 
incomplete follow-up of patients, which affects the intent-to-
treat analysis. 
  Two recent trials have shown that tiotropium reduces mor-
tality. A longitudinal, population-based cohort study was con-
ducted to compare the effect of tiotropium use and LABA 
use/OK? on all-cause mortality in patients with COPD [52]. 
Patients included individuals aged 65 or older discharged from 
hospital with a diagnosis of COPD. The effect of receiving a 
prescription for tiotropium compared to a LABA on all-cause 
mortality at 180 days post-hospital discharge was eliminated 
by controlling the potential confounders. Data from 7218 
eligible patients were analyzed. Of these, 1046 (14.5%) died 
in the follow-up period. Patients who received tiotropium were 
20% less likely to die than those receiving a LABA (hazard 
ratio 0.80, 95% CI 0.70 to 0.93). 
  In the UPLIFT study [29], vital-status information was 
available after a 45 month follow-up for 98% of patients in 
the tiotropium and for 97% in the placebo group (including 
patients who discontinued treatment). Tiotropium signifi-
cantly reduced mortality. Nine hundred and twenty-one pa-
tients died: 14.4% in the tiotropium group and 16.3% in the 
placebo group (hazard ratio, 0.87; 95% CI: 0.76 to 0.99) 
(Fig. 6). 
 
Fig. (6). Kaplan-Meier estimates of the probability of COPD death from any cause. From Tashkin et al. [29]. 
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RATE OF DECLINE IN LUNG FUNCTION 
  With the exception of smoking cessation, no intervention 
has been shown to decrease the rate of FEV1 decline in 
COPD [53]. Two identical 1-year, randomized, double blind, 
double-dummy studies involving 535 patients with COPD 
showed a sustained improvement in lung function. Tiotro-
pium (18 g once daily) increased trough FEV1 by 120 ml 
by the end of the trial, whereas treatment with ipratropium 
(40 g 4 times daily) was associated with a 30-ml reduction 
in trough FEV1 [26]. A post hoc analysis was performed 
using data from 921 patients [54]. The change in trough 
FEV1 was –12.4 ml/yr in the tiotropium group compared 
with –58.0 ml/yr in the placebo group (p = 0.005). Similar 
results were observed in both former and current smokers. In 
former smokers, the change in trough FEV1 was –17.0 ml/yr 
with tiotropium and –67.9 ml/yr with placebo (p = 0.011), 
whereas in smokers the changes in trough FEV1 were –3.8 
ml/yr and –40.5 ml/yr respectively (p = 0.19). The lack of 
statistically significant differences for FEV1 in smokers may 
be due to the small number of patients considered when the 
analysis was stratified by smoking status. 
  To determine whether tiotropium slows the decrease in 
lung function over time, a 4-year study [29] was performed. 
Therapy other than inhaled anticholinergic drugs was al-
lowed in accordance with current COPD guidelines. There 
were no significant differences between study groups in the 
rate of decline in the mean values for FEV1 and FVC either 
before or after bronchodilation from day 30 to the end of 
study (Fig. 7). In the tiotropium group, the mean values for 
FVC and FEV1 before and after bronchodilation showed 
significant improvements in FEV1 compared to the placebo 
group, ranging from 87 to 103 ml before bronchodilation and 
 
Fig. (7). Mean forced vital capacity in before and after bronchodilation from day 30 to the end of the study. From Tashkin et al. [29]. 
 
Fig. (8). Spearman rank correlations (rs) between the change in forced expiratory volume in one-second after 4 weeks of tiotropium bromide 
administration and (a) eosinophil percentages or (b) neutrophil percentages in induced sputum. Eosinophil and neutrophil percentages were 
determined prior tiotropium bromide administration. In all subjects (a) rs =0.669. p=0.003 and (b) rs =0.540. p=0.025. In smokers (a) rs 
=0.706. p=0.034 and (b) rs =0.361. p=0.339. In nonsmokers (a) rs =0.762. p=0.028 and (b) rs =0.762. p=0.028.  smokers; nonsmokers. 
From Iwamoto et al. [67]. 
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from 47 to 65 ml afterwards. The rate of decline in sub-
groups analyses showed no significant differences according 
to age, gender, smoking status, Gold stage and reversibility. 
In a post hoc analysis, between-group differences in the rate 
of decline in post-bronchodilator FEV1 were observed, with 
tiotropium again performing better than placebo (40 ± 3 ml 
in the tiotropium group and 47 ± 3 in the placebo group, p = 
0.046) in the subgroup of 1554 patients who were not receiv-
ing either inhaled corticosteroids or LABA at baseline. 
  Compared with results of previous long-term studies, the 
rate of decline in FEV1 observed in the UPLIFT study was 
numerically lower than those reported previously [55-58] 
and similar to those reported for healthy nonsmokers and 
sustained quitters with mild-to-moderate COPD [53] (Table 
1). 
  The current treatment for COPD may affect the decline in 
lung function and may have a ceiling effect, with the result 
that no further improvements are seen in the absence of an 
intervention that repairs or regenerates lung tissue [29]. 
SIDE EFFECTS OF TIOTROPIUM 
  Tiotropium has a wide therapeutic margin due to its poor 
gastrointestinal absorption and thus has very low systemic 
bioavailability. To date, no unfavorable interactions between 
tiotropium and other drugs have been reported. 
 Kesten  et al. [59] conducted a pooled analysis of adverse 
event data on 7819 patients with COPD from 19 randomized, 
double blind, placebo-control trials with tiotropium. Inher-
ently serious cardiac conditions such as cardiovascular mor-
tality (RR: 057; 95% CI: 0.26 to 1.26), cardiac arrest (RR: 
0.90; 95% CI: 0.26 to 3.15), and myocardial infarction (RR: 
0.74; 95% CI: 0.26 to 2.07) were not more frequent among 
patients receiving tiotropium than patients receiving placebo. 
Among heart rate and rhythm disorders, the relative risk of 
tachycardia (excluding ventricular tachycardia and fibrilla-
tion) was 1.68 (95% CI: 0.69 to 4.11) for any degree of the 
condition and 1.16 (95% CI: 0.33 to 0.43) for serious tachy-
cardia. The relative risk of left-heart failure among patients 
receiving tiotropium compared with patients receiving pla-
cebo was 0.46 (95% CI: 0.21 to 1.00). There was no increase 
in total and serious events due to ischemic heart disease. 
  For GI disorders, there was a higher risk of dry mouth in 
patients receiving tiotropium (RR, 3.60; 95% CI, 2.56 to 
5.05), but none was classified as serious. The relative risk of 
dysphagia was 5.91 (95% CI, 0.60 to 58.31). There was no 
increased risk of abdominal pain, constipation, dyspepsia, or 
nausea associated to tiotropium use. 
  Among renal and urinary disorders, the relative risk of 
urinary retention in patients receiving tiotropium compared 
to placebo was 10.93 (95% CI: 1.26 to 94.88). Although the 
relative risk of serious prostatic disorders was 5.32 (95% CI: 
0.59 to 48.33), the analysis of all selected events showed no 
association of tiotropium (RR: 1.04; 95% CI: 0.46 to 2.35). 
  As for skin disorders, the relative risk of pruritus in 
tiotropium users was 1.61 (95% CI: 0.68 to 3.82). There was 
no increase in the risk of serious events among these disor-
ders. An analysis of other selected events indicated no in-
creased risk of glaucoma, other visual disturbances, chest 
pain, edema, fungal infections, musculoskeletal and connec-
tive tissue disorders, central nervous system (CNS) or psy-
chiatric disorders. 
 In  UPLIFT  study, for all-cause mortality, the relative risk 
in patients receiving tiotropium compared to patients receiv-
ing placebo was 0.76 (95% CI: 0.50 to 1.16). The relative 
risk of cardiovascular mortality was 0.57 (95% CI: 0.26 to 
1.26) and of respiratory mortality was 0.71 (95% CI: 0.29 to 
1.74). 
  A recent publication [60] has raised concerns about the 
safety of tiotropium bromide. Assessing the results of a 
meta-analysis of 17 previously conducted clinical trials, 
Singh et al. suggested an association between inhaled anti-
cholinergics and an increased risk of cardiovascular death 
and myocardial infarction and stroke. However, the method-
ology of Singh et al.’s study raises several important con-
cerns. First, placebo controlled trials were considered to-
gether with active controlled trials, implicitly assuming that 
the comparator drug is interchangeable with a placebo. Sec-
ond, the analysis does not take into account the fact that in 
most trials more patients in the placebo group dropped out 
than patients taking active medication, and that they were 
followed for briefer periods of time, during which adverse 
events were reported. Third, most of the evidence in the 
analysis is from The Lung Health Study [61], in which most 
of the cardiovascular deaths occurred among patients who 
were not using their inhalers; clearly, these deaths could not 
be due to a medication they were not taking. Finally, the 
dataset analyzed appears to have an important methodologi-
cal flaw that potentially invalidates the findings: it appears to 
include two studies twice, thus double-counting more than 
one thousand patients. 
Table 1.  Result of Long-Term Studies in the Rate of Decline in FEV1 
 
Rate of Decline FEV1 (mL/y) 
Study  Active Smoker  FEV1 %  Drug of Study 
Dug Only  Placebo  Placebo* 
EUROSCOP 100%   79%  Budesonide  57  69  - 
ISOLDE 36-39%  50%  Fluticasone  50  59  - 
LHSII 90%   68%  Triamcinolone  44  47  - 
BRONCUS 41-51%   57%  NAC  54  47  - 
TORCH 43%   48%  S/F/SF  42/42/39  55  - 
UPLIFT 30%   47%  Tiotropium  40  -  42 
* All respiratory medications permitted throughout the trial, other than inhaled anticholinergics. Tiotropium Bromide  The Open Respiratory Medicine Journal, 2009, Volume 3    51 
  Two recent studies [29, 62] found that tiotropium was 
associated with reduced respiratory and overall mortality and 
was not associated with increased cardiac mortality. In the 
UPLIFT study [29], respiratory failure developed in 88 pa-
tients in the tiotropium group and in 120 in the placebo 
group (RR: 0.67; 95% CI: 0.51 to 0.89); myocardial infarc-
tion developed in 67 patients in the tiotropium group and in 
85 in the placebo group (relative risk, 0.73; 95% CI: 0.53 to 
1.00) and stroke developed in 82 patients in the tiotropium 
group and 80 in the placebo group (RR: 0.95; 95% CI: 0.70 
to 1.29). In summary, tiotropium seems to reduce the risk of 
mortality due to cardiac and vascular causes. Furthermore, it 
does not increase the risk of stroke and it may decrease the 
risk of myocardial infarction. 
THE ROLE OF TIOTROPIUM IN THE MANAGE-
MENT OF ASTHMA 
  Anticholonergic drugs inhibit reflex cholinergic bron-
choconstriction but are unable to significantly block the 
direct effects of inflammatory mediators such as histamine, 
kinins and leukotrienes on bronchial smooth muscle. This is 
why they are less effective bronchodilators in asthma than 
2-agonists. However, in a study of 12 atopic male asthmatic 
patients, tiotropium provided significant protection against a 
methacoline challenge for 48 h [63]. 
  Some subgroups of asthmatics seem to respond better to 
anticholinergics. Some authors aiming to identify these sub-
groups have suggested the following clinical profile: patients 
with nocturnal symptoms, chronic asthma showing concur-
rent fixed airway obstruction, intrinsic asthma with longer 
duration of disease and non-atopic asthma [63, 64]. Today, 
there are three trials that identify patients with asthma who 
respond to tiotropium: 
1. A genotype-stratified study revealed a greater bronchopro-
tective effect of anticholinergic agents in asthmatic patients 
with the Arg/Arg genotype of the 2-adrenergic receptor 
[65]. 
2. COPD and asthma are common and can occur in the same 
patient. In this case, chronic use of tiotropium achieves spi-
rometric improvements with symptomatic benefits, as seen 
by reduced need for rescue medication [66]. 
3. Iwamoto et al. [67] showed an association between re-
sponsiveness to tiotropium bromide and the presence of 
different inflammatory cells in the induced sputum of pa-
tients with severe persistent asthma treated with moderate-
to-high doses of inhaled corticosteroids and other anti-
asthma agents. The percentages of eosinophils in induced 
sputum were inversely correlated with FEV1, whereas the 
proportions of neutrophils were positively correlated with 
FEV1. Comparable results from nonsmoking asthmatics 
indicate a rationale for using tiotropium bromide to treat 
severe patients/with a noneosinophilic sputum profile (Fig. 
8). 
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